Search results
Dabigatran (Pradaxa®) Control Plasma (low range)
Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).
Dabigatran (Pradaxa®) Plasma Calibrator
Quantitative measurement of dabigatran, and anti-thrombin activities in plasma (e.g. Dabigatran Plasma Calibrator (ref. 222801), Dabigatran Control Plasma (ref. 224701), Argatroban Plasma Calibrator (ref. SC030K), Argatroban Control Plasma (ref. SC035K).
Dabigatran (Pradaxa®) Plasma Calibrator (low range)
Quantitative measurement of dabigatran, and anti-thrombin activities in plasma (e.g. Dabigatran Plasma Calibrator (ref. 222801), Dabigatran Control Plasma (ref. 224701), Argatroban Plasma Calibrator (ref. SC030K), Argatroban Control Plasma (ref. SC035K)).
Emicizumab Calibrator
Calibration of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
Emicizumab Controls
Quality control of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
FIBRIPHEN 1
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
FIBRIPHEN 2
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
FIBRIPHEN 5
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
Factor II (Prothrombin) Deficient Plasma
Measurement of factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.
Factor II (Prothrombin) Deficient Plasma
Measurement of Factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.